Oncology medicines
Category context
Oral and liquid oncology opportunities evaluated with specialist quality, demand, storage and regulatory requirements.
Products
A portfolio of governed decisions—not promises.
Every category remains subject to product rights, evidence, authorisation, qualified supply and confirmed availability.
Nutraxin UK catalogue reference
Food Supplement Portfolio Review
19 owner-supplied catalogue records for qualified B2B evaluation. No claim of UK availability, price, stock, permitted claims or medicinal status.
Strategic categories
Focus areas, not stock claims.
Each category states its evidence boundary.
Specialty medicines
Category context
Hard-to-source and clinically important categories considered through qualified B2B and regulatory pathways.
Oral liquid formulations
Category context
Technically differentiated liquid formulations requiring robust development, manufacturing and stability evidence.
Selected licensed generics
Category context
Established therapeutic categories assessed for compliant sourcing, documentation and commercial viability.
Cardiovascular medicines
Category context
Selected opportunities within a diversified future portfolio, not a statement of current availability.
Respiratory medicines
Category context
Potential licensed products assessed against source, device, packaging and applicable PLPI complexity.
Metabolic medicines
Category context
Selected categories considered for manufacturer or authorised-distributor partnerships.
Hospital & hard-to-source products
Category context
Qualified B2B enquiries reviewed without implying stock, authorisation or NHS supply.
Evidence gate
No category implies stock, approval or supply.
Representative imagery does not establish NovaPharm inventory, premises, employees or current partners.
Review the regulatory modelStart a qualified conversation